Repository logo
  • English
  • 中文
  • Log In
    New user? Click here to register.Have you forgotten your password?
Repository logo
    Communities & Collections
    Research Outputs
    Fundings & Projects
    People
    Organizations
    Statistics
  • English
  • 中文
  • Log In
    New user? Click here to register.Have you forgotten your password?
  1. Home
  2. .TMU Publications / 北醫出版品(教師升等著作 / 教學實踐 / 學位論文)
  3. .博碩士學位論文
  4. .94學年度
  5. 高糖誘發人類腹膜間皮細胞引起細胞凋亡路徑中粒線體所扮演的角色
 
  • Details
Options

高糖誘發人類腹膜間皮細胞引起細胞凋亡路徑中粒線體所扮演的角色

Other Title
Mitochondria in high glucose induced human peritoneal mesothelial cell apoptosis.
Type
thesis
Date Issued
2006
Author(s)
劉心雲
Advisor
高淑慧
洪冠予
Subjects
系所名稱:醫學檢驗生物技術學研究所
Abstract
在台灣,因末期腎病(end-stage renal disease, ESRD) 須要接受長期透析或移植治療的患者,約有四萬多人。腎臟病在國人十大死因中佔第七位;而慢性尿毒症的排行中,每年新發生率方面,台灣皆佔世界的第二位。Continuous ambulatory peritoneal dialysis (CAPD) 是末期腎臟衰竭病患治療方式中較方便且不影響病患生活方式,但是長期腹膜透析所引起的腹膜纖維化(peritoneal fibrosis,PF)是腹膜透析病人最常見的合併症之一,嚴重時甚至會影響生命。臨床上發現:目前使用的傳統腹膜透析溶液 (peritoneal dialysis ,PD solution) 具有高糖、高滲透壓、低酸鹼度,等透析液生物相容性不佳的問題。其中高濃度糖為腹膜透析溶液中可成功調整滲透壓達到脫水目的最主要成分。然而,目前台灣常用的糖濃度為1.5% (83.8mM)、2.5% (138mM)及4.25% (236mM)三種配製。人類腹膜間皮細胞 (human peritoneal mesothelial cell,HPMC) 長期暴露在這遠超過生理濃度的 glucose下會改變腹膜的結構與功能,造成人類腹膜間皮細胞逐漸脫落、細胞外間質(extracellular matrix ,ECM) 堆積、腹膜慢性發炎、間皮細胞的凋亡 (apoptosis),使腹膜剝離 (detachment)甚至功能衰敗。由先前的文獻指出 2.5%、4.25% glucose會引起人類腹膜間皮細胞壞死 (necrosis) 或細胞凋亡(apoptosis),但是其分子機制引發HPMC目前仍未明瞭,尤其粒線體以及活性氧物質所扮演的角色及調控機制也尚未被釐清。本論文研究主旨為高糖引起人類腹膜細胞凋亡路徑中粒線體所扮演的角色,我們推測高糖處理會經由粒線體氧化磷酸化反應(oxidative phosphorylation)產生活性氧自由基 (reactive oxygen species,ROS) 而引發細胞凋亡,我們於本研究發現經過 138mM glucose 及 236mM glucose 處理的人類腹膜細胞會引起細胞凋亡;以西方墨點法可觀察到人類腹膜細胞 cytochrome c release 增加、 PARP cleavage增加以及 caspase–9 、 caspase-3被活化,並且增加 collagen mRNA 3.66倍的表現。此外,我們亦進一步觀察,以大鼠環間膜細胞(rat glomerular mesangial cell,RMC)為細胞模式的實驗中將 35mM glucose添加1mM l-N-acetylcystein (L-NAC)、粒線體氧化磷酸化抑制劑1μM rotenone ;及1μM粒線體去偶合劑carbonyl cyanide m-chlorophenylhydrazone (CCCP) 可降低高糖刺激對RMC造成的傷害及分別減低細胞凋亡50%、60%、12%。我們的實驗結果可以解釋糖尿病腎臟病的可能原因,以及高糖透析液對 CAPD 患者長期使用對腹膜的不良影響,也可以作為日後研發藥物治療的理論基礎。
URI
https://203.71.86.71/handle/123456789/12432
https://hdl.handle.net/11296/8rjq67
File(s)
No Thumbnail Available
Name

C0178905.pdf

Size

9.7 MB

Format

Adobe PDF

Checksum

(MD5):75d4f0f40de0efb16d4b45dbacec6405

Copyright Notice

● The digital content on this platform is part of the Taipei Medical University Institutional Repository, featuring various academic works and outputs from the institution. It offers free access to academic research and public education for non-commercial use.

● Please use the content appropriately and within legal boundaries to respect copyright owners' rights. For commercial use, please obtain prior authorization from the copyright owner. Users must not use TMUIR for any illegal purposes.

● By utilising the platform, users are deemed to have fully accepted and understood all the regulations set out in this statement, relevant laws of the Republic of China, all international internet regulations, and usage conventions.

● TMUIR is committed to protecting the interests of copyright owners. If you believe that any material on this website infringes copyright, please contact our staff at libirtmu@gmail.com, and we will remove the work from the repository.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Cookie settings
  • Privacy policy
  • End User Agreement
  • Send Feedback